‘Make sure it never happens.’ Though presumptive House Speaker John Boehner (R-Ohio) says of healthcare reform, “there’s a lot of tricks up our sleeves in terms of how we can dent this, kick it, slow it down to make sure it never happens,” it is likely the law will remain intact in a divided Congress, according to the Washington Post.
More trouble for CROs. Pharmaceutical contract research organization Charles River Labs said it will cut an additional 4 percent of is 8,500-person workforce, or about 300 jobs, noting the global recession hit drug developers hard, causing them to cut all but the most essential programs, according to FierceBiotech.
J&J drops Arena Pharma. Johnson & Johnson cut its ties with San Diego-based Arena Pharmaceuticals to develop a diabetes drug after reviewing results from a Phase I clinical trial, according to Xconomy San Diego. A week ago, Arena and a different partner endured the FDA’s rejection of obesity drug, lorcaserin.
No partisanship here. Venture capitalists are difficult to define politically, according to Fortune‘s Term Sheet blog. On one hand, they are wealthy financiers who fit snugly in the Republican wheelhouse. On the other, most of them live in Democratic bastions like suburban Boston and Silicon Valley.
CT scans cut lung cancer risk. Annual CT scans of current and former heavy smokers reduced their risk of death from lung cancer by 20 percent, a huge government-financed study has found, The New York Times reports. The new test for the cancer, however, is not yet covered by insurance companies.
Zogenix lines up IPO. San Diego pharmaceutical company Zogenix is lining up an initial public offering that could raise up to $84 million to help it launch more products to treat central nervous system disorders and pain. The company’s first product, Sumavel DosePro, is a needle-free, single-dose device that delivers sumatriptan to treat migraine and cluster headache.